Related Experiment Video

Updated: Aug 14, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

[Vascular purpura in patients with chronic diffuse hepatic diseases]

A V Russkikh, L V Kozlovskaia, O G Krivosheev

    Klinicheskaia Meditsina
    |December 3, 2005
    PubMed

    Insights

    Vascular purpura (VP) is a common skin sign in chronic diffuse hepatic diseases (CDHD), appearing in 11% of patients. Its presence, especially at later stages, may indicate kidney involvement and impact prognosis.

    Area of Science:

    • Hepatology
    • Dermatology
    • Nephrology

    Background:

    • Chronic diffuse hepatic diseases (CDHD) encompass a range of liver conditions.
    • Cutaneous manifestations are common in CDHD, often serving as indicators of disease severity.
    • Vascular purpura (VP) is a specific type of cutaneous vasculitis observed in some CDHD patients.

    Purpose of the Study:

    • To assess the clinical significance of vascular purpura (VP) in diagnosing and prognosing chronic diffuse hepatic diseases (CDHD).
    • To determine the frequency and clinical implications of VP in a large cohort of CDHD patients.
    • To explore the relationship between VP, disease stage, and organ involvement in CDHD.

    Main Methods:

    • Retrospective analysis of 660 patients with CDHD of viral and non-viral origins.
    • Clinical observation and morphological data collection for patients with and without cutaneous vasculitis.
    • Statistical comparison of VP prevalence and associated factors between different CDHD subtypes and disease stages.

    Main Results:

    • 11% of CDHD patients exhibited vascular purpura (VP), a frequency comparable to other minor hepatic skin signs.
    • VP was observed in both viral (9.6%) and non-viral (14.2%) CDHD, including primary sclerosing cholangitis, autoimmune hepatitis, and Wilson-Konovalov disease.
    • VP predominantly manifested at the cirrhotic stage (84.3% of VP cases), with significantly higher renal involvement (32%) compared to patients without VP (11.4%).

    Conclusions:

    • Cutaneous vasculitis, including VP, is a universal sign in both viral and non-viral CDHD, relevant for diagnosis and prognosis.
    • The high incidence of VP in advanced liver disease stages suggests a role for liver dysfunction in its pathogenesis.
    • Increased renal involvement in CDHD patients with VP warrants consideration for prognostic assessment and management strategies.

    More Related Videos

    New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation08:45

    New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

    Published on: June 27, 2025

    Visualization of Vascular and Parenchymal Regeneration after 70% Partial Hepatectomy in Normal Mice11:10

    Visualization of Vascular and Parenchymal Regeneration after 70% Partial Hepatectomy in Normal Mice

    Published on: September 13, 2016

    Related Concept Videos

    Portal Hypertension01:22

    Portal Hypertension

    Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Cirrhosis II: Pathophysiology01:24

    Cirrhosis II: Pathophysiology

    Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
    Hepatic Portal System01:21

    Hepatic Portal System

    The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
    At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
    Diseases of the Liver and Gallbladder01:26

    Diseases of the Liver and Gallbladder

    Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
    Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...